120 related articles for article (PubMed ID: 8525537)
1. Long-term ganciclovir prophylaxis eliminates serious cytomegalovirus disease in liver transplant recipients receiving OKT3 therapy for rejection.
Winston DJ; Imagawa DK; Holt CD; Kaldas F; Shaked A; Busuttil RW
Transplantation; 1995 Dec; 60(11):1357-60. PubMed ID: 8525537
[TBL] [Abstract][Full Text] [Related]
2. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
Winston DJ; Busuttil RW
Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
[TBL] [Abstract][Full Text] [Related]
3. Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors.
Winston DJ; Busuttil RW
Transplantation; 2004 Jan; 77(2):305-8. PubMed ID: 14742998
[TBL] [Abstract][Full Text] [Related]
4. Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation.
Valenza M; Czer LS; Pan SH; Aleksic I; Freimark D; Harasty DA; Admon D; Barath P; Blanche C; Trento A
J Heart Lung Transplant; 1995; 14(4):659-65. PubMed ID: 7578172
[TBL] [Abstract][Full Text] [Related]
5. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
6. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
Said T; Nampoory MR; Johny KV; Pacsa AS; Mini Abraham P; Nair MP; Abdel-Haleem M; Samhan M; Al-Mousawi M
Transplant Proc; 2004; 36(6):1847-9. PubMed ID: 15350495
[TBL] [Abstract][Full Text] [Related]
8. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B
J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406
[TBL] [Abstract][Full Text] [Related]
9. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
[TBL] [Abstract][Full Text] [Related]
10. Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with CMV-seropositive donors.
Seu P; Winston DJ; Holt CD; Kaldas F; Busuttil RW
Transplantation; 1997 Dec; 64(11):1614-7. PubMed ID: 9415569
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen.
Thomas LD; Milstone AP; Miller GG; Loyd JE; Stephen Dummer J
Clin Transplant; 2009; 23(4):476-83. PubMed ID: 19453645
[TBL] [Abstract][Full Text] [Related]
12. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
[TBL] [Abstract][Full Text] [Related]
13. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial.
Paya CV; Wilson JA; Espy MJ; Sia IG; DeBernardi MJ; Smith TF; Patel R; Jenkins G; Harmsen WS; Vanness DJ; Wiesner RH
J Infect Dis; 2002 Apr; 185(7):854-60. PubMed ID: 11920308
[TBL] [Abstract][Full Text] [Related]
14. A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients.
Nafar M; Pezeshki ML; Farrokhi F; Einollahi B; Pour-Reza-Gholi F; Firouzan A; Farhangi S
Transplant Proc; 2005 Sep; 37(7):3053-5. PubMed ID: 16213302
[TBL] [Abstract][Full Text] [Related]
15. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir.
Palmer SM; Grinnan DC; Diane Reams B; Steele MP; Messier RH; Duane Davis R
Clin Transplant; 2004 Apr; 18(2):179-85. PubMed ID: 15016133
[TBL] [Abstract][Full Text] [Related]
16. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
[TBL] [Abstract][Full Text] [Related]
17. Preemptive therapy with intravenous ganciclovir for the prevention of cytomegalovirus disease in lung transplant recipients.
Monforte V; Román A; Gavaldà J; Bravo C; Gispert P; Pahissa A; Morell F
Transplant Proc; 2005 Nov; 37(9):4039-42. PubMed ID: 16386621
[TBL] [Abstract][Full Text] [Related]
18. Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis.
Nicholson VA; Whimbey E; Champlin R; Abi-Said D; Przepiorka D; Tarrand J; Chan K; Bodey GP; Goodrich JM
Bone Marrow Transplant; 1997 Jan; 19(1):37-41. PubMed ID: 9012929
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients.
Ahsan N; Holman MJ; Yang HC
Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699
[TBL] [Abstract][Full Text] [Related]
20. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients.
Pavlopoulou ID; Syriopoulou VP; Chelioti H; Daikos GL; Stamatiades D; Kostakis A; Boletis JN
Clin Microbiol Infect; 2005 Sep; 11(9):736-43. PubMed ID: 16104989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
